McKesson Corporation (MCK) Q1 FY2027 Financial Statements: Revenue $105.38B, Net income $614.00M
More for McKesson: Company index · 10-K and 10-Q summary · 8-K filings and events
PeriodQ1 FY2027
Published
McKesson reported $105.38 billion in revenue for Q1 FY2027, the quarter ended June 30, 2026, up 7.7% from a year earlier, with gross profit of $3.69 billion, up 12.4%, and operating income of $1.32 billion, up 27.3%. Most of that operating income increase came from the absence of a prior-year bad-debt provision on the Rite Aid bankruptcy, which sat in selling, distribution, general and administrative expenses a year earlier. Net income attributable to McKesson fell to $614 million, down 21.7%, and diluted earnings per share to $5.15 from $6.25. McKesson attributes that decline principally to non-cash adjustments remeasuring redeemable noncontrolling interests to redemption value, the larger relating to the June 2026 sale of a minority stake in its Medical-Surgical Solutions business to funds managed by affiliates of Apollo Global Management and a smaller one to the Core Ventures business, items that sit below operating income. On the company's own adjusted basis, which excludes those remeasurements and other items, both operating profit and earnings per diluted share rose, and McKesson raised its fiscal 2027 adjusted earnings per diluted share guidance range.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $105,380,000,000 | up 7.7% |
| Net income | $614,000,000 | down 21.7% |
| Diluted EPS | $5.15 | down 17.6% |
| Operating income | $1,319,000,000 | up 27.3% |
| Gross profit | $3,685,000,000 | up 12.4% |
About this file
| Ticker | MCK |
|---|---|
| CIK | 0000927653 |
| Company | McKesson Corporation |
| Business type | healthcare distributor |
| Schema template | standard operating company (revenue / cost of sales / gross profit / operating income), extended with reportable-segment revenue and operating profit |
| Reporting currency | USD |
| Converted to USD | no |
| Units | actual dollars (not millions); per-share amounts in dollars; share counts in actual shares |
MCK annual income statement, balance sheet and cash flow
| FY2026 | FY2025 | FY2024 | |
|---|---|---|---|
| Fiscal year | 2026 | 2025 | 2024 |
| Label | FY2026 | FY2025 | FY2024 |
| Period start | 2025-04-01 | 2024-04-01 | 2023-04-01 |
| Period end | 2026-03-31 | 2025-03-31 | 2024-03-31 |
| Period type | fiscal year | fiscal year | fiscal year |
| Source accession | 0000927653-26-000069 | 0000927653-26-000069 | 0000927653-26-000069 |
| Income statement | |||
| Revenues | 403,430,000,000 | 359,051,000,000 | 308,951,000,000 |
| Cost of sales | 388,880,000,000 | 345,728,000,000 | 296,123,000,000 |
| Gross profit | 14,550,000,000 | 13,323,000,000 | 12,828,000,000 |
| Selling distribution general and administrative expenses | 8,096,000,000 | 8,507,000,000 | 8,657,000,000 |
| Claims and litigation charges net | -3,000,000 | 108,000,000 | 147,000,000 |
| Restructuring impairment and related charges net | 245,000,000 | 286,000,000 | 115,000,000 |
| Total operating expenses | 8,338,000,000 | 8,901,000,000 | 8,919,000,000 |
| Operating income | 6,212,000,000 | 4,422,000,000 | 3,909,000,000 |
| Other income net | 236,000,000 | 202,000,000 | 132,000,000 |
| Interest expense | 247,000,000 | 265,000,000 | 252,000,000 |
| Income before income taxes | 6,201,000,000 | 4,359,000,000 | 3,789,000,000 |
| Income tax expense | 1,102,000,000 | 878,000,000 | 629,000,000 |
| Net income | 5,099,000,000 | 3,481,000,000 | 3,160,000,000 |
| Net income attributable to noncontrolling interests | 337,000,000 | 186,000,000 | 158,000,000 |
| Net income attributable to mckesson | 4,762,000,000 | 3,295,000,000 | 3,002,000,000 |
| Diluted EPS | 38.38 | 25.72 | 22.39 |
| Basic EPS | 38.55 | 25.86 | 22.54 |
| Diluted shares | 124,100,000 | 128,100,000 | 134,100,000 |
| Basic shares | 123,600,000 | 127,400,000 | 133,200,000 |
| Dividends declared per common share | 3.17 | 2.75 | 2.4 |
| Cash flow | |||
| Net cash provided by operating activities | 6,155,000,000 | 6,085,000,000 | 4,314,000,000 |
| Payments for property plant and equipment | 436,000,000 | 537,000,000 | 431,000,000 |
| Capitalized software expenditures | 309,000,000 | 322,000,000 | 256,000,000 |
| Acquisitions net of cash acquired | 3,416,000,000 | 24,000,000 | 272,000,000 |
| Proceeds from sales of businesses and investments net | 830,000,000 | 179,000,000 | 47,000,000 |
| Net cash used in investing activities | -3,432,000,000 | -733,000,000 | -1,072,000,000 |
| Proceeds from issuances of long term debt | 1,990,000,000 | 498,000,000 | 991,000,000 |
| Repayments of long term debt | 1,207,000,000 | 519,000,000 | 288,000,000 |
| Share repurchases | 4,750,000,000 | 3,146,000,000 | 3,025,000,000 |
| Dividends paid | 381,000,000 | 345,000,000 | 314,000,000 |
| Net cash provided by financing activities | -4,631,000,000 | -3,965,000,000 | -3,342,000,000 |
| Capital expenditures derived | 745,000,000 | 859,000,000 | 687,000,000 |
| Free cash flow | 5,410,000,000 | 5,226,000,000 | 3,627,000,000 |
| Segment revenues | |||
| North american pharmaceutical | 336,652,000,000 | 304,507,000,000 | 261,368,000,000 |
| Oncology and multispecialty | 48,423,000,000 | 36,862,000,000 | 30,490,000,000 |
| Prescription technology solutions | 5,805,000,000 | 5,216,000,000 | 4,769,000,000 |
| Medical surgical solutions | 11,507,000,000 | 11,380,000,000 | 11,309,000,000 |
| Other | 1,043,000,000 | 1,086,000,000 | 1,015,000,000 |
| Segment operating profit | |||
| North american pharmaceutical | 3,658,000,000 | 2,945,000,000 | 2,338,000,000 |
| Oncology and multispecialty | 1,149,000,000 | 767,000,000 | 707,000,000 |
| Prescription technology solutions | 1,044,000,000 | 875,000,000 | 835,000,000 |
| Medical surgical solutions | 938,000,000 | 779,000,000 | 955,000,000 |
| Other | 590,000,000 | 54,000,000 | 57,000,000 |
| Total reportable segment operating profit | 7,379,000,000 | 5,420,000,000 | 4,892,000,000 |
| Corporate expenses net | 931,000,000 | 796,000,000 | 851,000,000 |
| Balance sheet | |||
| Cash and cash equivalents | 3,975,000,000 | 5,691,000,000 | |
| Receivables net | 27,985,000,000 | 25,643,000,000 | |
| Inventories net | 24,207,000,000 | 23,001,000,000 | |
| Total current assets | 57,210,000,000 | 55,398,000,000 | |
| Property plant and equipment net | 2,668,000,000 | 2,502,000,000 | |
| Goodwill | 11,316,000,000 | 10,022,000,000 | |
| Intangible assets net | 4,079,000,000 | 1,464,000,000 | |
| Total assets | 82,323,000,000 | 75,140,000,000 | |
| Drafts and accounts payable | 59,973,000,000 | 55,330,000,000 | |
| Current portion of long term debt | 1,267,000,000 | 1,191,000,000 | |
| Total current liabilities | 67,017,000,000 | 61,604,000,000 | |
| Long term debt | 5,259,000,000 | 4,463,000,000 | |
| Long term litigation liabilities | 5,091,000,000 | 5,601,000,000 | |
| Redeemable noncontrolling interests | 943,000,000 | 0 | |
| Total mckesson stockholders deficit | -2,172,000,000 | -2,074,000,000 | |
| Noncontrolling interests | 395,000,000 | 380,000,000 | |
| Total equity including noncontrolling interests | -1,777,000,000 | -1,694,000,000 | |
| Total debt | 6,526,000,000 | 5,654,000,000 | |
| Total liabilities derived | 83,157,000,000 | 76,834,000,000 | |
MCK quarterly income statement, balance sheet and cash flow
| Q1 FY2027 | Q1 FY2026 | |
|---|---|---|
| Label | Q1 FY2027 | Q1 FY2026 |
| Period start | 2026-04-01 | 2025-04-01 |
| Period end | 2026-06-30 | 2025-06-30 |
| Period type | three months | three months |
| Source accession | 0000927653-26-000234 | 0000927653-26-000234 |
| Income statement | ||
| Revenues | 105,380,000,000 | 97,827,000,000 |
| Cost of sales | 101,695,000,000 | 94,548,000,000 |
| Gross profit | 3,685,000,000 | 3,279,000,000 |
| Selling distribution general and administrative expenses | 2,264,000,000 | 2,196,000,000 |
| Claims and litigation charges net | -34,000,000 | 0 |
| Restructuring impairment and related charges net | 136,000,000 | 47,000,000 |
| Total operating expenses | 2,366,000,000 | 2,243,000,000 |
| Operating income | 1,319,000,000 | 1,036,000,000 |
| Other income net | 66,000,000 | 64,000,000 |
| Interest expense | 77,000,000 | 49,000,000 |
| Income before income taxes | 1,308,000,000 | 1,051,000,000 |
| Income tax expense | 276,000,000 | 220,000,000 |
| Net income | 1,032,000,000 | 831,000,000 |
| Net income attributable to noncontrolling interests | 418,000,000 | 47,000,000 |
| Net income attributable to mckesson | 614,000,000 | 784,000,000 |
| Diluted EPS | 5.15 | 6.25 |
| Basic EPS | 5.17 | 6.28 |
| Diluted shares | 119,200,000 | 125,500,000 |
| Basic shares | 118,700,000 | 124,900,000 |
| Dividends declared per common share | 0.82 | 0.71 |
| Cash flow | ||
| Net cash provided by operating activities | -220,000,000 | -918,000,000 |
| Payments for property plant and equipment | 112,000,000 | 111,000,000 |
| Capitalized software expenditures | 40,000,000 | 78,000,000 |
| Acquisitions net of cash acquired | 23,000,000 | 3,359,000,000 |
| Proceeds from sales of businesses and investments net | 9,000,000 | 4,000,000 |
| Net cash used in investing activities | -214,000,000 | -3,564,000,000 |
| Proceeds from issuances of long term debt | 3,215,000,000 | 1,990,000,000 |
| Repayments of long term debt | 1,000,000 | 0 |
| Share repurchases | 2,530,000,000 | 581,000,000 |
| Dividends paid | 102,000,000 | 90,000,000 |
| Sale of noncontrolling interest in medical surgical solutions net | 1,238,000,000 | 0 |
| Net cash provided by financing activities | 1,632,000,000 | 1,176,000,000 |
| Capital expenditures derived | 152,000,000 | 189,000,000 |
| Free cash flow | -372,000,000 | -1,107,000,000 |
| Segment revenues | ||
| North american pharmaceutical | 86,773,000,000 | 82,729,000,000 |
| Oncology and multispecialty | 14,222,000,000 | 10,658,000,000 |
| Prescription technology solutions | 1,566,000,000 | 1,434,000,000 |
| Medical surgical solutions | 2,819,000,000 | 2,701,000,000 |
| Other | 0 | 305,000,000 |
| Segment operating profit | ||
| North american pharmaceutical | 903,000,000 | 594,000,000 |
| Oncology and multispecialty | 325,000,000 | 212,000,000 |
| Prescription technology solutions | 226,000,000 | 253,000,000 |
| Medical surgical solutions | 122,000,000 | 221,000,000 |
| Other | 0 | 13,000,000 |
| Total reportable segment operating profit | 1,576,000,000 | 1,293,000,000 |
| Corporate expenses net | 191,000,000 | 193,000,000 |
| Balance sheet | ||
| Cash and cash equivalents | 5,164,000,000 | |
| Receivables net | 30,316,000,000 | |
| Inventories net | 26,259,000,000 | |
| Total current assets | 62,837,000,000 | |
| Property plant and equipment net | 2,684,000,000 | |
| Goodwill | 11,278,000,000 | |
| Intangible assets net | 4,013,000,000 | |
| Total assets | 88,330,000,000 | |
| Drafts and accounts payable | 63,731,000,000 | |
| Current portion of long term debt | 1,297,000,000 | |
| Total current liabilities | 70,356,000,000 | |
| Long term debt | 8,432,000,000 | |
| Long term litigation liabilities | 5,058,000,000 | |
| Redeemable noncontrolling interests | 2,563,000,000 | |
| Total mckesson stockholders deficit | -4,240,000,000 | |
| Noncontrolling interests | 376,000,000 | |
| Total equity including noncontrolling interests | -3,864,000,000 | |
| Total debt | 9,729,000,000 | |
| Total liabilities derived | 89,631,000,000 | |
MCK trailing twelve month income statement and cash flow
| Twelve months ended June 30, 2026 | |
|---|---|
| Label | Twelve months ended June 30, 2026 |
| Period start | 2025-07-01 |
| Period end | 2026-06-30 |
| Period type | trailing twelve months |
| Source accession | 0000927653-26-000234 |
| Income statement | |
| Revenues | 410,983,000,000 |
| Cost of sales | 396,027,000,000 |
| Gross profit | 14,956,000,000 |
| Operating income | 6,495,000,000 |
| Net income | 5,300,000,000 |
| Net income attributable to noncontrolling interests | 708,000,000 |
| Net income attributable to mckesson | 4,592,000,000 |
| Diluted EPS derived | 37.28 |
| Cash flow | |
| Net cash provided by operating activities | 6,853,000,000 |
| Capital expenditures derived | 708,000,000 |
| Free cash flow | 6,145,000,000 |
| Derivation | fiscal 2026 (year ended March 31, 2026) plus the three months ended June 30, 2026, less the three months ended June 30, 2025 |
| Source accessions | 0000927653-26-000069; 0000927653-26-000234 |
Adjustments
| Value | |
|---|---|
| Splits applied | none |
| ADR ratio | n/a |
| FX | none - McKesson reports in U.S. dollars |
Notes
- Figures come from two filings: McKesson's fiscal 2026 Form 10-K (accession 0000927653-26-000069, filed May 8, 2026), which presents the years ended March 31, 2026, 2025 and 2024, and the Form 10-Q for the first quarter of fiscal 2027 (accession 0000927653-26-000234, filed August 5, 2026), which presents the three months ended June 30, 2026 and June 30, 2025.
- McKesson's fiscal year ends March 31, so fiscal 2027 began April 1, 2026 and the quarter ended June 30, 2026 is the first quarter of fiscal 2027.
- Fiscal 2024 carries no balance sheet here because the 10-K's balance sheet presents only March 31, 2026 and March 31, 2025. For the same reason the quarter ended June 30, 2025 carries an income statement and cash flow statement but no balance sheet: the 10-Q's balance sheet presents June 30, 2026 and March 31, 2026.
- Because this is the first quarter of the fiscal year, the year-to-date column and the quarter are the same period, so no separate year-to-date block is reported.
- Sign convention: the statements print costs, expenses, taxes and the noncontrolling-interest allocation in parentheses as deductions; those lines are recorded here as positive amounts. 'Claims and litigation charges, net' is the one line that can go either way, and it is recorded as a positive charge and a negative amount when it is a net credit - fiscal 2026 (a $3 million net credit) and the quarter ended June 30, 2026 (a $34 million net credit) were both net credits. Cash flow subtotals and capital-markets lines keep the statement's own signs, except that capital expenditures, acquisitions, debt repayments, share repurchases and dividends paid are stated as positive outflows.
- Capital expenditures are the sum of the two lines the cash flow statement prints - payments for property, plant, and equipment and capitalized software expenditures - and free cash flow is operating cash flow less that total. For fiscal 2026 that is $6,155 million less $745 million, or $5,410 million.
- The balance sheet does not print a total liabilities subtotal, so total liabilities is derived as total assets less redeemable noncontrolling interests less total deficit; it equals the sum of the printed liability captions ($83,157 million at March 31, 2026 and $89,631 million at June 30, 2026).
- McKesson reports a stockholders' deficit rather than positive equity, the cumulative result of share repurchases: total deficit including noncontrolling interests was negative $1,777 million at March 31, 2026 and negative $3,864 million at June 30, 2026. Redeemable noncontrolling interests sit outside the deficit, so the balance sheet balances as liabilities plus redeemable noncontrolling interests plus total deficit.
- The trailing-twelve-month view is derived, not a filed column: fiscal 2026 plus the June 2026 quarter less the June 2025 quarter. Its diluted earnings per share is the same roll-forward of the reported per-share amounts ($38.38 plus $5.15 less $6.25).
- The quarter ended June 30, 2026 shows a sharp split between operating and attributable earnings. Operating income rose 27% to $1,319 million and consolidated net income rose to $1,032 million, but net income attributable to McKesson fell to $614 million from $784 million, because net income attributable to noncontrolling interests jumped to $418 million from $47 million. That allocation includes $374 million of adjustments to the redemption value of redeemable noncontrolling interests - $293 million for Medical-Surgical Solutions and $81 million for Core Ventures - as the 10-Q's noncontrolling interests note sets out.
- On June 1, 2026 McKesson completed the sale of an approximately 13% minority interest in its Medical-Surgical Solutions business to funds managed by affiliates of Apollo Global Management for approximately $1.25 billion of convertible preferred equity, shown as $1,238 million of net proceeds in financing activities. The interest is classified as a redeemable noncontrolling interest, which is why that balance rose to $2,563 million from $943 million; McKesson retains control and continues to consolidate the business.
- Operating cash flow is negative in the June quarter in both years (negative $220 million in fiscal 2027 and negative $918 million in fiscal 2026) because of the seasonal build in receivables and inventories; the full fiscal year generated $6,155 million.
- Segment figures follow the structure McKesson adopted in the second quarter of fiscal 2026 - North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions and Medical-Surgical Solutions, with the former Norwegian operations in Other. All prior-period segment information in these filings has been recast onto that structure; consolidated revenues, income and cash flows were not restated.
- Segment operating profit is measured before interest expense and income taxes and is reconciled in the filings to income before income taxes by deducting corporate expenses, net and interest expense; segment revenues and segment operating profit are therefore not directly comparable to the consolidated operating income line.
- The quarter's figures are taken from the 10-Q rather than from the results release furnished on August 5, 2026 (accession 0000927653-26-000232); the two agree on revenues, operating income, net income and diluted earnings per share.
- Dividends per share are the amounts declared, as stated in the statements of stockholders' deficit: $3.17, $2.75 and $2.40 for fiscal 2026, 2025 and 2024, and $0.82 for the June 2026 quarter against $0.71 a year earlier.
Uncertainties
- No balance sheet is reported for fiscal 2024 or for the quarter ended June 30, 2025, because neither filing presents one for those dates.
- Total liabilities is derived rather than printed; the balance sheet stops at the individual liability captions.
- Trailing-twelve-month figures are arithmetic on filed periods, not a column McKesson filed. Trailing diluted earnings per share of $37.28 is the roll-forward of reported per-share amounts; trailing net income attributable to McKesson of $4,592 million divided by the fiscal 2026 weighted-average diluted share count of 124.1 million would give $37.00, the roll-forward being higher because the share count fell through the year rather than because of a difference in earnings.
- Capital expenditures here combine payments for property, plant, and equipment with capitalized software expenditures. The segments note reports a separately defined measure, 'expenditures for long-lived assets', which happens to equal that total in every period shown ($745 million, $859 million and $687 million for fiscal 2026, 2025 and 2024, and $152 million and $189 million for the June 2026 and June 2025 quarters), but the two are defined differently and need not agree in other periods.
- Dividends per share are declared amounts taken from the statements of stockholders' deficit, not cash dividends paid, which appear separately in financing activities.
Company details
| Value | |
|---|---|
| Name | Mckesson Corp |
| Ticker | MCK |
| CIK | 0000927653 |
| Exchange | NYSE |
| State | Texas |
| Incorporation | Delaware |
| SIC | 5122 |
| Office | Trade & Services |
| Industry | Wholesale-Drugs, Proprietaries & Druggists' Sundries |
Fiscal period
| FY2027 | |
|---|---|
| Fiscal year | 2027 |
| Fiscal period | Q1 |
| Tag | FY27Q1 |
| Period end | 2026-06-30 |
| Form | 10-Q |
| Accession | 0000927653-26-000234 |
| Fiscal year end | 0331 |
| Source | facts |
Source filings
| Role | Current | Form | Fiscal year | Fiscal period | Tag | Period end | Filed | Accession | Url | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| annual | no | 10-K | 2026 | FY | FY26 | 2026-03-31 | 2026-05-08 | 0000927653-26-000069 | https://www.sec.gov/Archives/edgar/data/927653/000092765326000069/0000927653-26-000069-index.htm | reported |
| quarterly | yes | 10-Q | 2027 | Q1 | FY27Q1 | 2026-06-30 | 2026-08-05 | 0000927653-26-000234 | https://www.sec.gov/Archives/edgar/data/927653/000092765326000234/0000927653-26-000234-index.htm | facts |
FAQ · McKesson financial statements
How much revenue did McKesson report in Q1 FY2027?
McKesson reported $105.38 billion in revenue for Q1 FY2027, the quarter ended June 30, 2026. That is up 7.7% from $97.83 billion in the same quarter a year earlier, driven by higher volumes in North American pharmaceutical distribution and by specialty growth in the Oncology and Multispecialty segment.
What was McKesson's earnings per share in Q1 FY2027?
McKesson reported diluted earnings per share of $5.15 for Q1 FY2027, the quarter ended June 30, 2026, down from $6.25 a year earlier. Net income attributable to McKesson was $614 million, down 21.7%.
Why did McKesson's profit fall in Q1 FY2027 even though revenue grew?
Net income attributable to McKesson fell to $614 million in Q1 FY2027, down 21.7%, principally because of non-cash adjustments remeasuring redeemable noncontrolling interests to redemption value, the larger relating to the June 2026 sale of a minority stake in its Medical-Surgical Solutions business and a smaller one to the Core Ventures business. Those adjustments sit below operating income and are absorbed in the earnings attributed to noncontrolling interests, which is what leaves less for McKesson even though operating income itself rose to $1.32 billion, up 27.3%.
What was McKesson's gross profit in Q1 FY2027?
McKesson earned gross profit of $3.69 billion on revenue of $105.38 billion in Q1 FY2027, the quarter ended June 30, 2026, the very thin spread characteristic of pharmaceutical wholesale distribution. Gross profit was up 12.4% from $3.28 billion a year earlier, growing faster than revenue, which was up 7.7%.
Where can I get McKesson Corporation (MCK) financial data in machine-readable form?
Ticker Scout publishes McKesson Corporation's financial statements as JSON at https://tickerscout.ai/mck/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/mck/narrative.md and https://tickerscout.ai/mck/events.md. McKesson Corporation's SEC CIK is 0000927653. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does McKesson Corporation (MCK) next file with the SEC?
McKesson Corporation (MCK) is expected to file its next Form 10-Q with the SEC on or around November 5, 2026. That date is a projection rather than a company-announced date: it is derived from McKesson Corporation's own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q1 FY2027, the period ended 2026-06-30, SEC accession 0000927653-26-000234.
How this page was built
This page was built from three of McKesson Corporation's own filings with the SEC, read one at a time. Nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names five such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Built from McKesson Corporation's SEC filings by Ticker Scout; accession numbers are cited throughout so every figure can be checked against sec.gov. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.